# Hangzhou Heda Industry Fund

> Hangzhou Heda Industry Fund is a VC fund backing Biotechnology and Medical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Sep 2025
- Lead investor: 13%
- Last updated: Aug 2026

Hangzhou Heda Industry Fund is an investment firm.

## Contacts

5 contacts available for Hangzhou Heda Industry Fund. Shizune tracks 1 team members at Hangzhou Heda Industry Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hangzhou-heda-industry-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Medical | 3 | 38% |
| Health Care | 3 | 38% |
| Pharmaceutical | 3 | 38% |
| Manufacturing | 2 | 25% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Series B | 3 | 38% |
| Seed | 1 | 13% |
| Venture - Series Unknown | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Mr. Jin Yufeng | President | 6 | https://shizune.co/investors/profile/mr-jin-yufeng |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SEED | SEED is a company engaged in the research and development and production of foldable ultra-thin flexible glass (UTG). |  | Series B | Sep 12, 2025 |  |
| Chance Pharmaceuticals | Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders. |  | Venture - Series Unknown | Mar 04, 2025 |  |
| Medtech Technology | Medtech Technology is a firm that develops innovative ophthalmic medical devices.It has developed its own artificial lens production and research technology platform, as well as a technological barrier to high-end artificial lens manufacture. | $28.2M | Series B | Sep 14, 2024 |  |
| Hegea Bio | Hegeia Biotechnology is a company that focused on the research and development of siRNA, tiny nucleic acid attached delivery medicines. | $13.8M | Series A | Mar 28, 2024 |  |
| Hengyu Biotechnology | Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. | $27.8M | Series B | Mar 11, 2024 |  |
| Ceram Pharmaceuticals | Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases. | $14M | Series A | Dec 25, 2023 |  |
| Innolake Biopharm | Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas. | $14.1M | Series A | Jun 05, 2023 |  |
| Blue Wave | Blue Wave is a producer of Industrial IoT and Internet of Vehicles chips. | $14.5M | Seed | May 04, 2023 |  |

8 of 8 investments shown.

## Co-investors
- [Anchuang Investment](https://shizune.co/investors/profile/anchuang-investment) — VC Fund, 1 deal together
- [Black Oak Capital](https://shizune.co/investors/profile/black-oak-capital) — VC Fund, 1 deal together
- [Chengdu Jiaozi Financial Holding](https://shizune.co/investors/profile/chengdu-jiaozi-financial-holding) — VC Fund, 1 deal together
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 1 deal together
- [CS Capital](https://shizune.co/investors/profile/cs-capital) — VC Fund, 1 deal together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hangzhou Heda Industry Fund invest in?

Hangzhou Heda Industry Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hangzhou Heda Industry Fund?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hangzhou Heda Industry Fund?

The team at Hangzhou Heda Industry Fund includes Mr. Jin Yufeng (President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co